PMID- 33062025
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220417
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Yiqi Yangyin Huoxue Method in Treating IdiopathicPulmonary Fibrosis: A Systematic 
      Review and Meta-Analysis of Randomized Controlled Trials.
PG  - 8391854
LID - 10.1155/2020/8391854 [doi]
LID - 8391854
AB  - OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is a common respiratory disease 
      that can lead to respiratory failure in severe condition. Despite notable 
      advances in its treatment, some patients show poor effect when treated with 
      conventional western medicine (CWM). Traditional Chinese medicine with the Yiqi 
      Yangyin Huoxue method (YQYYHXM) has been reported to be positive for IPF. In 
      order to explore the effectiveness and safety of YQYYHXM in the treatment of IPF, 
      we performed this meta-analysis. METHOD: We searched six databases including 
      Embase, Cochrane, PubMed, CNKI, Wan Fang, and VIP database from their inception 
      to June 1, 2019, and then selected eight studies. Two reviewers independently 
      conducted methodological evaluation and data analysis by the software RevMan 
      5.3.3 and Stata 12.0. RESULTS: The meta-analysis revealed that when YQYYHXM was 
      adopted in combination with CWM, cough, chest pain, and shortness of breath of 
      IPF patients improved significantly. After treatment with YQYYHXM combined with 
      CWM, the SGRQ of IPF patients substantially enhanced. YQYYHXM also has positive 
      effect on 6MWD and TLC, but the improvement on FVC was not obvious. In addition, 
      YQYYHXM has no significance in improving PaO(2). All the adverse events were 
      reported in the control group. CONCLUSION: YQYYHXM is more effective and safe as 
      adjunctive treatment for patients with IPF. However, in the future, long-term, 
      large-scale, and high-quality trials will be required to provide more convincing 
      evidence of YQYYHXM due to some limitations of this review.
CI  - Copyright (c) 2020 Min Zhou et al.
FAU - Zhou, Min
AU  - Zhou M
AD  - College of Clinical Medical, Jiangxi University of Traditional Chinese Medicine, 
      Nanchang, China.
FAU - Ye, Chao
AU  - Ye C
AUID- ORCID: 0000-0002-0125-3670
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, 
      Nanchang, China.
FAU - Liang, Qijun
AU  - Liang Q
AUID- ORCID: 0000-0002-2922-5823
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, 
      Nanchang, China.
FAU - Pei, Qiulan
AU  - Pei Q
AD  - Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, 
      Nanchang, China.
FAU - Xu, Fan
AU  - Xu F
AD  - College of Clinical Medical, Jiangxi University of Traditional Chinese Medicine, 
      Nanchang, China.
FAU - Wen, Hang
AU  - Wen H
AD  - College of Clinical Medical, Shanghai University of Traditional Chinese Medicine, 
      Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201003
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7548958
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/10/17 06:00
MHDA- 2020/10/17 06:01
PMCR- 2020/10/03
CRDT- 2020/10/16 05:53
PHST- 2020/04/18 00:00 [received]
PHST- 2020/07/19 00:00 [revised]
PHST- 2020/07/27 00:00 [accepted]
PHST- 2020/10/16 05:53 [entrez]
PHST- 2020/10/17 06:00 [pubmed]
PHST- 2020/10/17 06:01 [medline]
PHST- 2020/10/03 00:00 [pmc-release]
AID - 10.1155/2020/8391854 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 Oct 3;2020:8391854. doi: 
      10.1155/2020/8391854. eCollection 2020.